Why Syapse?
Syapse enterprise platform (Syapse Oncology) allows healthcare systems to implement precision oncology programs, enabling oncologists to deliver personalized care to every patient. The data Syapse collects and networks from siloded hospital and laboratory enterprise systems and at the point of care (Syapse Network) allows Syapse to provide solutions for pharma, CROs, etc. (ecosystem partners) including real world evidence generation, identification of patients for clinical trials and hub services. Syapse customers are leading healthcare providers, such as Intermountain Healthcare, Dignity Health, CHI, Providence,, University of Miami Health System and Aurora Health Care. Current ecosystem partners include Roche and Medidata.
Market Opportunity
While Syapse’s platform can be applied to any disease area, early customers have focused on oncology. In October 2015, Oliver Wyman estimated that the market opportunity for Precision Medicine hubs is $200 billion annually.
Company Milestones
- Syapse becomes a Safeguard partner company
- Syapse’s platform is selected by the American Society of Clinical Oncology (ASCO) for its Targeted Agent and Profiling Utilization Registry (TAPUR) Study
- Syapse partners with PierianDX to accelerate precision medicine programs for health systems
- Syapse announces collaboration with Caris Life Sciences for oncology data aggregation
- Syapse raises $25 million in Series C funding with participation from Safeguard Scientifics
- Syapse launches Global Partner Program to enhance and accelerate the implementation of the Syapse Precision Medicine Platform at healthcare organizations globally
- Syapse partners with Henry Ford Health System to launch oncology precision medicine program
- Syapse partners with Catholic Health Initiatives to launch a national oncology precision medicine program
- Syapse Announces Ken Tarkoff as New CEO
